AMGN vs UPB
AMGN: Amgen is a leading biotechnology firm dedicated to developing innovative human therapeutics to address critical unmet needs in areas like oncology, inflammation, and cardiovascular disease. UPB: Upstream Bio is a clinical-stage biotech developing verekitug, a potentially best-in-class TSLP receptor antagonist designed to offer superior efficacy and convenient quarterly dosing for severe respiratory diseases.
Side-by-side fundamentals
| Metric | AMGN | UPB | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $407.44 | $4.55 | |
| Market cap | $220.3B | $249M | |
| P/E as of 2026-10-08 | 25.30 | n/a | |
| Net margin FY2025, SEC XBRL | +21.0% | -5026.0% | AMGN higher |
| Operating margin FY2025, SEC XBRL | +24.7% | -5618.8% | AMGN higher |
| ROE FY2025, SEC XBRL | +89.1% | -42.2% | AMGN higher |
| ROA FY2025, SEC XBRL | +8.5% | -40.5% | AMGN higher |
| Debt / equity as of 2026-09-03 | 4.90 | 0.00 | UPB lower |
| Revenue growth (YoY) as of 2026-09-03 | +9.1% | +13.2% | UPB higher |
| Revenue CAGR (3y) SEC XBRL | +11.8% | +9.5% | AMGN higher |
| Dividend yield as of 2026-09-03 | +2.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 15 | 0 | AMGN higher |
| Beta as of 2026-09-03 | 0.42 | 1.12 | |
| 1-year return as of 2026-10-08 close | +38.3% | -76.0% | AMGN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.